Raynovent

About Raynovent

Raynovent is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for liver and respiratory diseases. Established in October 2018 as a sino-foreign joint venture, Raynovent operates as a subsidiary of the A-share listed company Guangdong Zhongsheng Pharmaceutical Co., Ltd. and is headquartered in Guangzhou, China.

The company was co-founded by Chairman Chaofeng Long, who holds a Master of Clinical Pharmacology from Peking University Health Science Center and has over 20 years of experience in new drug R&D. Co-founder, Director, and President Dr. Xiaoxin Chen holds a Doctor of Medicine from Guangzhou University of Chinese Medicine and previously served as Director of the Innovative Medicine Division at Guangdong Zhongsheng Pharmaceutical. The third co-founder, Senior Vice President Haijun Li, is a certified clinician with a Master's in Medicine from the Second Military Medical University and has over a decade of experience in the clinical development of innovative drugs.

Raynovent's business model is centered on the research, development, and eventual commercialization of novel therapies for diseases with significant unmet medical needs, such as influenza, COVID-19, non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), and obesity. The company's pipeline includes several candidates in clinical or pre-clinical stages. Key assets include ZSP1273 (Onradivir), an RNA polymerase inhibitor for influenza A, and RAY1216 (Leritrelvir), a 3CL protease inhibitor for COVID-19, both of which have advanced to Phase III trials. Another prominent candidate is ZSP1601, a first-in-class drug for NASH that has entered Phase IIb clinical trials. The company is also developing ZSP0678 for NASH and Primary Biliary Cholangitis (PBC).

The company has successfully raised significant capital to fund its clinical trials and commercialization preparations. Notable funding rounds include a Series A in 2018/2019, a Series B of nearly $300 million in December 2020, and a Series C round of ¥370 million (US$54 million) in January 2023. This funding supports the acceleration of its lead candidates through late-stage clinical trials.